Evidence map›Paper›PMID 42789078›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026

Pantoprazole as a potential repurposed drug targeting the adenosinergic system in esophageal cancer.

Adriana Simioni, Rafael D Weimer, Julia B de Souza, Isadora V Citrini, Julia A da Rosa, Kaline Cardoso, Maria E Delawi, Luis Fsm Timmers, Fernanda B Morrone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adriana SimioniLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Rafael D WeimerLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Julia B de SouzaLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Isadora V CitriniLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Julia A da RosaLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Kaline CardosoLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil.
Maria E DelawiPrograma de Pós-graduação em Biotecnologia, Univates, Lajeado, RS, Brasil.
Luis Fsm TimmersPrograma de Pós-graduação em Biotecnologia, Univates, Lajeado, RS, Brasil.
Fernanda B MorroneLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde e da Vida, PUCRS, Porto Alegre, RS, Brasil. fernanda.morrone@pucrs.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer remains a major global health burden and is associated with poor prognosis. Adenosine signaling, particularly through CD73 and P1 receptors, contributes to tumor progression and immune modulation. Pantoprazole, a proton pump inhibitor widely used in clinical practice, has recently been suggested as a potential modulator of adenosinergic pathways. This study investigated the ability of pantoprazole to modulate adenosine signaling. In silico docking analyses were performed to assess the binding of pantoprazole to adenosine P1 receptors and CD73, followed by in vitro assays using esophageal adenocarcinoma (OE33) and squamous cell carcinoma (KYSE450) cell lines to evaluate cell growth, adenosinergic signaling, and tumor-related cellular functions following pantoprazole treatment. Docking analyses identified CD73 and P1 receptors, particularly A

Indexed as

AdenosineAntineoplastic AgentsDrug RepositioningEsophageal NeoplasmsPantoprazoleReceptors, Purinergic P15'-NucleotidaseCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorGPI-Linked ProteinsHumansMolecular Docking Simulation5'-NucleotidaseAdenosineAntineoplastic AgentsGPI-Linked ProteinsPantoprazoleReceptors, Purinergic P1Adenosinergic systemDrug repurposingEsophageal cancerP1 receptorsPantoprazole

Identifiers

PMID42789078
PMCPMC13668930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.